Mizuho Initiates Coverage On Sutro Biopharma with Outperform Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Positive 82.4%

Neg 0% Neu 0% Pos 82.4%

Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Outperform rating and announces Price Target of $50.